Warning: The NCBI web site requires JavaScript to function. more...
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
Breast Cancer Res. 2009;11(1):R11. Epub 2009 Feb 24.
Related citations
Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
Cancer. 2006 Aug 15;107(4):696-704.
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
Clin Cancer Res. 2005 Mar 15;11(6):2163-8.
Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS, Kim SW.
Oncol Rep. 2007 Jul;18(1):139-43.
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2008;10(1):R2. Epub 2008 Jan 8.
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.
Am J Pathol. 2010 Oct;177(4):1647-56. Epub 2010 Sep 2.
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.
Med Oncol. 2009 Dec;26(4):480-90. Epub 2009 Jan 7.
Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.
Hum Pathol. 2012 Jan;43(1):23-30. Epub 2011 Jul 20.
Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.
Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G.
Virchows Arch. 2011 Jul;459(1):1-10. Epub 2011 Jun 4.
CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.
Albasri A, Aleskandarany M, Benhasouna A, Powe DG, Ellis IO, Ilyas M, Green AR.
Breast Cancer Res Treat. 2011 Feb;126(1):47-54.
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G, Obrist P, Ensinger C, Theurl I, Dünser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G.
Int J Cancer. 2002 Apr 20;98(6):883-8.
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK.
Gynecol Oncol. 2005 Nov;99(2):415-21. Epub 2005 Sep 12.
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, Baselga J, Clinton GM.
Clin Cancer Res. 2006 Jan 15;12(2):424-31.
Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.
Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O, Hiraide H, Mochizuki H.
Cancer Sci. 2006 Jul;97(7):597-604.
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer.
Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P.
Ann Oncol. 2010 May;21(5):955-60. Epub 2009 Nov 25.
Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
Taniyama K, Ishida K, Toda T, Motoshita J, Kuraoka K, Saito A, Tani Y, Uike T, Teramoto S, Koseki M.
Breast Cancer. 2008;15(3):231-40. Epub 2008 Feb 9.
Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL.
Cancer. 2003 Apr 15;97(8):1841-8.
Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.
Clin Cancer Res. 2008 Oct 15;14(20):6625-33.
[Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
Liu C, Zhou S, Ke CS, Li NP, Wu RL.
Ai Zheng. 2007 Sep;26(9):929-36. Chinese.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on